COVID-19与流感住院患者动脉及静脉血栓事件风险比较
该回顾性队列研究基于美国FDA Sentinel系统(2家全国性健康保险公司和4个地区综合健康系统数据),纳入疫苗可用前(2020年4–11月)COVID-19住院患者41 443例、疫苗可用期间(2020年12月–2021年5月)COVID-19住院患者44 194例及流感住院患者(2018年10月–2019年4月)8269例。采用倾向评分精细分层加权Cox回归比较90天动脉血栓栓塞(急性心肌梗死或缺血性卒中)和静脉血栓栓塞(深静脉血栓或肺栓塞)风险。结果显示,COVID-19住院患者90天静脉血栓栓塞风险显著高于流感患者(疫苗可用前校正HR 1.60,95%CI 1.43–1.79;疫苗可用期间校正HR 1.89,95%CI 1.68–2.12),而动脉血栓栓塞风险无显著差异(校正HR 1.04,95%CI 0.97–1.11;校正HR 1.07,95%CI 1.00–1.14)。提示COVID-19住院患者需关注静脉血栓栓塞风险。
要点
- COVID-19住院患者90天静脉血栓栓塞绝对风险:疫苗可用前9.5%(95%CI 9.2%–9.7%),疫苗可用期间10.9%(95%CI 10.6%–11.1%),均高于流感患者的5.3%(95%CI 4.9%–5.8%)。
- 校正后静脉血栓栓塞风险COVID-19仍显著高于流感:疫苗可用前校正HR 1.60(95%CI 1.43–1.79),疫苗可用期间校正HR 1.89(95%CI 1.68–2.12)。
- 动脉血栓栓塞风险COVID-19与流感无显著差异:疫苗可用前校正HR 1.04(95%CI 0.97–1.11),疫苗可用期间校正HR 1.07(95%CI 1.00–1.14)。
- 动脉血栓栓塞绝对风险:流感14.4%(95%CI 13.6%–15.2%),COVID-19疫苗可用前15.8%(95%CI 15.5%–16.2%),疫苗可用期间16.3%(95%CI 16.0%–16.6%)。
- 研究基于美国FDA Sentinel系统回顾性队列,结果提示COVID-19住院患者90天内静脉血栓栓塞风险显著高于流感住院患者。
适用人群与场景
- 疫苗可用前(2020年4–11月)COVID-19住院患者41 443例,疫苗可用期间(2020年12月–2021年5月)COVID-19住院患者44 194例,流感住院患者(2018年10月–2019年4月)8269例;数据来自美国FDA Sentinel系统(2家全国性健康保险公司和4个地区综合健康系统)。
- COVID-19或流感通过医院诊断或核酸检测识别。
研究设计与关键结果
- 研究类型:回顾性队列研究;总样本85 637例COVID-19患者(平均年龄72岁,SD 13.0;50.5%男性)和8269例流感患者(平均年龄72岁,SD 13.3;45.0%男性)。
- 主要终点:90天内动脉血栓栓塞(急性心肌梗死或缺血性卒中)和静脉血栓栓塞(深静脉血栓或肺栓塞)的医院诊断。
- 动脉血栓栓塞90天绝对风险:流感14.4%(95%CI 13.6%–15.2%)vs COVID-19疫苗可用前15.8%(95%CI 15.5%–16.2%),风险差1.4%(95%CI 1.0%–2.3%);vs COVID-19疫苗可用期间16.3%(95%CI 16.0%–16.6%),风险差1.9%(95%CI 1.1%–2.7%)。
- 动脉血栓栓塞校正后风险:与流感相比,COVID-19疫苗可用前校正HR 1.04(95%CI 0.97–1.11),疫苗可用期间校正HR 1.07(95%CI 1.00–1.14),均无显著差异。
- 静脉血栓栓塞90天绝对风险:流感5.3%(95%CI 4.9%–5.8%)vs COVID-19疫苗可用前9.5%(95%CI 9.2%–9.7%),风险差4.1%(95%CI 3.6%–4.7%);vs COVID-19疫苗可用期间10.9%(95%CI 10.6%–11.1%),风险差5.5%(95%CI 5.0%–6.1%)。
- 静脉血栓栓塞校正后风险:与流感相比,COVID-19疫苗可用前校正HR 1.60(95%CI 1.43–1.79),疫苗可用期间校正HR 1.89(95%CI 1.68–2.12),均显著升高。
证据类型、等级与局限
- 证据类型:回顾性队列研究,基于美国FDA Sentinel系统数据;采用倾向评分精细分层加权Cox回归估计校正HR。
- 局限:原文未报告局限性。
对床旁实践的改变
- 基于美国公共卫生监测系统数据,COVID-19住院(疫苗可用前及疫苗可用期间)与流感住院(2018–2019年)相比,90天内静脉血栓栓塞风险显著升高,动脉血栓栓塞风险无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The incidence of arterial thromboembolism and venous thromboembolism in persons with COVID-19 remains unclear.
OBJECTIVE: To measure the 90-day risk of arterial thromboembolism and venous thromboembolism in patients hospitalized with COVID-19 before or during COVID-19 vaccine availability vs patients hospitalized with influenza.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 41 443 patients hospitalized with COVID-19 before vaccine availability (April-November 2020), 44 194 patients hospitalized with COVID-19 during vaccine availability (December 2020-May 2021), and 8269 patients hospitalized with influenza (October 2018-April 2019) in the US Food and Drug Administration Sentinel System (data from 2 national health insurers and 4 regional integrated health systems).
EXPOSURES: COVID-19 or influenza (identified by hospital diagnosis or nucleic acid test).
MAIN OUTCOMES AND MEASURES: Hospital diagnosis of arterial thromboembolism (acute myocardial infarction or ischemic stroke) and venous thromboembolism (deep vein thrombosis or pulmonary embolism) within 90 days. Outcomes were ascertained through July 2019 for patients with influenza and through August 2021 for patients with COVID-19. Propensity scores with fine stratification were developed to account for differences between the influenza and COVID-19 cohorts. Weighted Cox regression was used to estimate the adjusted hazard ratios (HRs) for outcomes during each COVID-19 vaccine availability period vs the influenza period.
RESULTS: A total of 85 637 patients with COVID-19 (mean age, 72 [SD, 13.0] years; 50.5% were male) and 8269 with influenza (mean age, 72 [SD, 13.3] years; 45.0% were male) were included. The 90-day absolute risk of arterial thromboembolism was 14.4% (95% CI, 13.6%-15.2%) in patients with influenza vs 15.8% (95% CI, 15.5%-16.2%) in patients with COVID-19 before vaccine availability (risk difference, 1.4% [95% CI, 1.0%-2.3%]) and 16.3% (95% CI, 16.0%-16.6%) in patients with COVID-19 during vaccine availability (risk difference, 1.9% [95% CI, 1.1%-2.7%]). Compared with patients with influenza, the risk of arterial thromboembolism was not significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.04 [95% CI, 0.97-1.11]) or during vaccine availability (adjusted HR, 1.07 [95% CI, 1.00-1.14]). The 90-day absolute risk of venous thromboembolism was 5.3% (95% CI, 4.9%-5.8%) in patients with influenza vs 9.5% (95% CI, 9.2%-9.7%) in patients with COVID-19 before vaccine availability (risk difference, 4.1% [95% CI, 3.6%-4.7%]) and 10.9% (95% CI, 10.6%-11.1%) in patients with COVID-19 during vaccine availability (risk difference, 5.5% [95% CI, 5.0%-6.1%]). Compared with patients with influenza, the risk of venous thromboembolism was significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.60 [95% CI, 1.43-1.79]) and during vaccine availability (adjusted HR, 1.89 [95% CI, 1.68-2.12]).
CONCLUSIONS AND RELEVANCE: Based on data from a US public health surveillance system, hospitalization with COVID-19 before and during vaccine availability, vs hospitalization with influenza in 2018-2019, was significantly associated with a higher risk of venous thromboembolism within 90 days, but there was no significant difference in the risk of arterial thromboembolism within 90 days.
参考来源
- Lo Re V, Dutcher SK, Connolly JG, et al. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients. JAMA. 2022. PMID: 35972486. doi:10.1001/jama.2022.13072
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。